Results for placebobehandling translation from Swedish to English

i dessa studier jämfördes behandling med halocur med placebobehandling.
7 westferry circus, canary wharf, london e14 4hb, uk tel.

i en pivotal studie jämfördes eculizumabbehandling med en studiearm med placebobehandling.
there was one pivotal trial comparing the eculizumab-treatment arm to a placebo-treatment arm.

varje patients cfa72h under placebobehandling användes som deras cfa72hvärde utan behandling.
each patient’s cfa-72h during placebo treatment was used as their no-treatment cfa-72h value.

jämfört med placebobehandling, ledde behandlingen med replagal även till en minskad ackumulation av gb3.
compared with placebo, treatment with replagal also reduced accumulation of gb3.

ameluz jämfördes även med placebobehandling i en randomiserad, dubbelblind klinisk prövning som rekryterade 122 patienter.
ameluz was also compared with placebo treatment in a randomised, double-blind clinical trial enrolling 122 patients.

3 fick placebobehandling rapporterades 128 infusionsrelaterade reaktioner hos 21 av 32 patienter efter administrering av totalt 1 612 infusioner.
in the placebo treatment group 128 infusion- related reactions were reported in 21 out of 32 patients following administration of a total of 1612 infusions.

jämförelsen gjordes istället med en grupp patienter som hade behandlats med en placebobehandling som ingick i ett annat oberoende försök.
the comparison was done instead with a group of patients who had been treated with a dummy treatment as part of another, unrelated trial.

patienterna fick endera ett 700 mikrograms eller ett 350 mikrograms ozurdex-implantat, eller också fick de placebobehandling.
patients were given either a 700 microgram or a 350 microgram implant of ozurdex or they received a sham treatment.

det primära effektmåttet var medeldifferensen i koefficienten för fettabsorption (cfa72h) mellan behandling med enzepi och placebobehandling.
the primary efficacy endpoint was the mean difference in the coefficient of fat absorption (cfa-72h) between enzepi and placebo treatment.

dessa biverkningar rapporterades i allmänhet första gången under de första två veckorna av behandlingen och graden av avbrutna ropinirolbehandlingar var låg och ungefär densamma som för placebobehandling.
these events were generally first reported during the initial two weeks of treatment and the rate of discontinuation from ropinirole treatment was low and similar to that from placebo treatment.

patienterna fick antingen ozurdex-implantat eller placebobehandling, vilken skedde med hjälp av en applikator som sattes mot ögat men utan att någonting injicerades.
the patients were given an ozurdex implant or they received a ‘sham’ treatment where an applicator was pressed against their eye but nothing was actually injected.

eftersom sjukdomen är mycket allvarlig var det av etiska skäl inte möjligt att jämföra cystagon direkt med en placebobehandling (overksam behandling).
because the disease is very serious, it was not possible for ethical reasons to compare cystagon directly to a dummy treatment.

i kliniska prövningar vid en rad olika indikationer inklusive allergisk rinit och kronisk idiopatisk urtikaria vid den rekommenderade dosen 5 mg dagligen rapporterades biverkningar med neoclarityn hos 3 % fler patienter än vid placebobehandling.
in clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with neoclarityn were reported in 3 % of patients in excess of those treated with placebo.

vid den rekommenderade dosen i kliniska prövningar som omfattade vuxna och ungdomar vid en rad olika indikationer inklusive allergisk rinit och kronisk idiopatisk urtikaria rapporterades biverkningar med neoclarityn hos 3 % fler patienter än vid placebobehandling.
at the recommended dose, in clinical trials involving adults and adolescents in a range of indications including allergic rhinitis and chronic idiopathic urticaria, undesirable effects with neoclarityn were reported in 3 % of patients in excess of those treated with placebo.

jämfört med placebobehandling, återfanns cirka 25% mindre s- 7- oh- warfarinmetabolit i urinen hos försökspersoner som behandlades med lumiracoxib.
compared to placebo treatment, recovery of the s-7-oh warfarin metabolite in urine was about 25% lower in subjects treated with lumiracoxib.

fler patienter förblev rökfria efter behandling med champix än efter placebobehandling: bland dem som hade tagit champix var 23% fortfarande rökfria och motsvarande siffra för dem som tagit placebo var 9%.
40 weeks after the end of the treatment period, the percentage of patients who were still non-smokers was 23% among those who had taken champix, and 9% among those who had taken a placebo.

studien visade fördelaktig effekt för memantinbehandling jämfört med placebobehandling vid 6 månader (observed cases analys avseende cibic-plus (clinician's interview based impression of change)): p=0,025; adcs-adlsev (alzheimer's disease cooperative study - activities of daily living): p=0,003; sib (severe impairment battery): p=0,002).
the study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (cibic-plus): p = 0.025; alzheimer’s disease cooperative study – activities of daily living (adcs-adlsev): p = 0.003; severe impairment battery (sib): p = 0.002).